RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
NEW YORK, Jan. 08, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Osiris Therapeutics, Inc. (NASDAQ:OSIR) securities from May 12, 2014 through November 20, 2015, all dates inclusive (the “Class Period”) of the important January 22, 2016 lead plaintiff deadline in the class action filed by the firm. The lawsuit seeks to recover damages for Osiris investors under the federal securities laws.
To join the Osiris class action, go to the firm’s website at http://rosenlegal.com/cases-786.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or email [email protected] or [email protected] for more information on the class action. The case is pending in the U.S. District Court for the Southern District of New York.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Osiris improperly recognized revenue under contracts it had with its distributors; (2) Osiris’ disclosure controls and procedures were not effective as of December 31, 2014, March 31, 2015, and June 30, 2015; and (3) as a result, defendants’ statements about Osiris’ business and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 22, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-786.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
